Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathing in xenon gas could reveal hidden lung damage

NCT ID NCT05914506

Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether a special MRI scan using xenon gas can spot early signs of lung scarring and heart strain in people with progressive lung fibrosis. About 30 adults already on anti-fibrotic medication will be scanned and followed over time. The goal is to see if this imaging method can detect disease activity and predict who will worsen, potentially leading to earlier and better treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who have recently recieved a diagnosis of progressive fibrosing interstial lung disease and are expected to recieve antifibrotic therapy

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed signed consent * Age 18-90 * Pre-menopausal women must be confirmed non-pregnant by an onsite test. * Patients diagnosed with IPF or fibrotic ILD who fulfills PPF criteria, and are prescribed antifibrotic treatment. * Cognitively able to understand and participate in the study Exclusion Criteria: * Contraindications for MRI: * Pacemaker, neurostimulator or cochlear implant * Metal foreign bodies such as fragments and irremovable piercings * Unsafe medical implants (safety of heart valves, hips and the like must be confirmed) * Intrathoracic clips or coils * Cardiac pacemakers * Claustrophobia * Largest circumference including arms \> 160 cm * Contraindications to gadolinium contrast * eGFR \< 30 mL/min/1.73m2 * Previous adverse reactions to gadolinium * Overlapping emphysemic disease where the emphysema-component outweighs the fibrosis * Unable to perform breath-hold of minimum 20 seconds. * Allergy to Xenon * Breast feeding * Evidence of ongoing respiratory infections at time of MR examinations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibrosing interstitial lung disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Progressive fibrosing interstitial lung disease

Contacts and locations

Locations

  • Aarhus University, Department of Clinical Medicine, MR Research Centre

    Aarhus, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.